Efavirenz and CYP2B6 polymorphism:: Implications for drug toxicity and resistance

被引：38
|
作者：
Nolan, D
Phillips, E
Mallal, S
机构：
[1] Murdoch Univ, Ctr Clin Immunol & Biomed Stat, Royal Perth Hosp, Perth, WA 6000, Australia
[2] Univ British Columbia, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V5Z 1M9, Canada
来源：
CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 03期
关键词：
D O I：
10.1086/499369
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：408 / 410
页数：3
相关论文
共 50 条
  • [41] ROLE OF CYP2B6 POLYMORPHISM IN THE METABOLISM AND PHARMACOKINETICS OF METHADONE ENANTIOMERS
    Somogyi, A. A.
    Coller, J. K.
    Foster, D. B. F.
    Li, Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 32 - 32
  • [42] Molecular simulation study of CYP2B6 polymorphism with and without psoralen
    Lu, Nan
    Meng, Fancui
    Xu, Weiren
    Tang, Lida
    Xu, Youjun
    MOLECULAR SIMULATION, 2018, 44 (17) : 1402 - 1410
  • [43] The Cyp2b6 Gene Polymorphism and Phenotypic Correlation of Efavirenz-Based Combination Therapy Among the Niger Delta Ethnic Population: Implications in Modern Pharmacogenomics
    Bunu, Samuel J.
    Owaba, Azibanasamesa D. C.
    Vaikosen, Edebi N.
    Ebeshi, Benjamin U.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2022, 15 : 45 - 54
  • [44] CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women
    Roehrich, Carola R.
    Droegemoeller, Britt I.
    Ikediobi, Ogechi
    van der Merwe, Lize
    Grobbelaar, Nelis
    Wright, Galen E. B.
    McGregor, Nathaniel
    Warnich, Louise
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 (06) : 529 - 538
  • [45] CRYSTAL STRUCTURE OF CYP2B6 IN COMPLEX WITH AN EFAVIRENZ ANALOG: FROM PLASTICITY TO PI INTERACTIONS IN CYP2B ENZYMES
    Shah, Manish B.
    Halpert, James R.
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S32 - S33
  • [46] Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine
    Colic, Antoinette
    Alessandrini, Marco
    Pepper, Michael S.
    DRUG METABOLISM REVIEWS, 2015, 47 (02) : 111 - 123
  • [47] THE EXTENT OF INHIBITION AND INDUCTION OF CYP2B6 BY EFAVRIENZ IS CYP2B6 GENOTYPE-DEPENDENT
    Duong, A.
    Gufford, B.
    Masters, A.
    Burgess, K.
    Lu, J.
    Metzger, I.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S36 - S36
  • [48] CYP2B6 genetic polymorphism and its impact on efavirenz plasma levels in HIV/AIDS out-patients of African origin
    Ebeshi, Benjamin U.
    Oluka, Margaret
    Bolaji, Oluseye O.
    Guantai, Anastasia N.
    Masimirembwa, Collen M.
    DRUG METABOLISM REVIEWS, 2011, 43 : 174 - 174
  • [49] Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series
    Park-Wyllie, LY
    Antoniou, T
    AIDS, 2003, 17 (04) : 638 - 640
  • [50] CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
    Milcah Dhoro
    Simbarashe Zvada
    Bernard Ngara
    Charles Nhachi
    Gerald Kadzirange
    Prosper Chonzi
    Collen Masimirembwa
    BMC Pharmacology and Toxicology, 16
12345